The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,006
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Aguirre, V., Uchida, T., Yenush, L., Davis, R., & White, M. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.9047 · Cited by 1,487
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Self-citationAn enzyme-release assay for natural cytotoxicity
Korzeniewski, C., & Callewaert, D. M. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90438-6 · Cited by 1,076
Dysregulation of the TSC-mTOR pathway in human disease
Inoki, K., Corradetti, M. N., & Guan, K.-L. (2005) · Nature Genetics · doi:10.1038/ng1494 · Cited by 972
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 853
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M. P., Backer, J. M., Natt, F., Bos, J. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506925102 · Cited by 757
The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665
Features of Selective Kinase Inhibitors
Knight, Z. A., & Shokat, K. M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.04.011 · Cited by 657
Self-citationEkstrand, A. J., Sugawa, N., James, C. D., & Collins, V. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4309 · Cited by 602
PI 3-kinase p110β: a new target for antithrombotic therapy
Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1232 · Cited by 580
Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G. B., & Kondo, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3640 · Cited by 534
hVps34 Is a Nutrient-regulated Lipid Kinase Required for Activation of p70 S6 Kinase
Byfield, M. P., Murray, J. T., & Backer, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507201200 · Cited by 527
An expanding role for mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.007 · Cited by 523
Phosphoinositide 3-kinase signalling – which way to target?
Wymann, M. P., Zvelebil, M., & Laffargue, M. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00163-9 · Cited by 411
Imatinib as a Paradigm of Targeted Therapies
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91001-9 · Cited by 370
Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D., & Yan, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1170 · Cited by 337
Zheng, X.-F., Fiorentino, D., Chen, J., Crabtree, G. R., & Schreiber, S. L. (1995) · Cell · doi:10.1016/0092-8674(95)90058-6 · Cited by 301
Ueki, K., Fruman, D. A., Brachmann, S. M., Tseng, Y.-H., Cantley, L. C., & Kahn, C. R. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.3.965-977.2002 · Cited by 285
CCI‐779 in metastatic melanoma: A Phase II trial of the California Cancer Consortium
Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., Gajewski, T., Quirt, I., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 227
DNA Repair: The Importance of Phosphorylating Histone H2AX
Lowndes, N. F., & Toh, G. W.-L. (2005) · Current Biology · doi:10.1016/j.cub.2005.01.029 · Cited by 206
Schlegel, J., Merdes, A., Stumm, G., Albert, F. K., Forsting, M., Hynes, N., & Kiessling, M. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560114 · Cited by 201
Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C., & Cantley, L. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1596-1607.2005 · Cited by 179
Selective role of PI3Kδ in neutrophil inflammatory responses
Sadhu, C., Dick, K. O., Tino, W. T., & Staunton, D. E. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01480-3 · Cited by 142
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
Knight, Z. A., Chiang, G. G., Alaimo, P. J., Kenski, D. M., Ho, C., Coan, K., Abraham, R. T., & Shokat, K. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.06.022 · Cited by 137
Self-citationFunctional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA
Czauderna, F., Fechtner, M., Aygün, H., Arnold, W., Klippel, A., Giese, K., & Kaufmann, J. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg141 · Cited by 91
Therapeutic potential of target of rapamycin inhibitors
Easton, J. B., & Houghton, P. J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.6.551 · Cited by 84
Altered molecular pathways in gliomas: An overview of clinically relevant issues
Rao, R. D., & James, C. D. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.07.002 · Cited by 83
Wong, S., McLaughlin, J., Cheng, D., Zhang, C., Shokat, K. M., & Witte, O. N. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407061101 · Cited by 72
Self-citationTORgeting oncogene addiction for cancer therapy
Choo, A. Y., & Blenis, J. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.021 · Cited by 62
Agosti, R. M., Leuthold, M., Gullick, W. J., et al. (1992) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf01600211 · Cited by 61
Gupta, N., Scharenberg, A. M., Fruman, D. A., Cantley, L. C., Kinet, J.-P., & Long, E. O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.7489 · Cited by 60
Aoki, M., & Vogt, P. K. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-18930-2_19 · Cited by 13
Cited by
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Metadata
- Authors
- Fan, Q.-W., Knight, Z. A., Goldenberg, D. D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 9
- Issue
- 5
- Pages
- 341-349
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2109467838
- Cited by
- 585
- References
- 44
- FWCI
- 24.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.